These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1342 related items for PubMed ID: 12709467

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.
    JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.
    Biol Psychiatry; 2004 Nov 01; 56(9):670-6. PubMed ID: 15522251
    [Abstract] [Full Text] [Related]

  • 6. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 01; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 7. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
    Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, Vassilopoulos D.
    Eur J Neurol; 2007 Feb 01; 14(2):168-73. PubMed ID: 17250725
    [Abstract] [Full Text] [Related]

  • 8. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.
    Methods; 2012 Apr 01; 56(4):484-93. PubMed ID: 22503777
    [Abstract] [Full Text] [Related]

  • 9. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
    Seppälä TT, Louhija UM, Appelberg B, Herukka SK, Juva K.
    Am J Geriatr Psychiatry; 2014 Sep 01; 22(9):908-16. PubMed ID: 23597931
    [Abstract] [Full Text] [Related]

  • 10. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Sep 01; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 11. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z, Kálmán J, Tóth ME, Zvara Á, Sántha M, Ivitz E, Janka Z, Pákáski M.
    J Alzheimers Dis; 2015 Sep 01; 44(4):1303-12. PubMed ID: 25428253
    [Abstract] [Full Text] [Related]

  • 12. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.
    Neurobiol Aging; 2006 Sep 01; 27(9):1202-11. PubMed ID: 16085339
    [Abstract] [Full Text] [Related]

  • 13. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
    Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM.
    JAMA Neurol; 2014 Jul 01; 71(7):855-62. PubMed ID: 24818585
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillán C, Yébenes JG, del Ser T.
    Arch Neurol; 2003 Sep 01; 60(9):1218-22. PubMed ID: 12975286
    [Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
    Fortea J, Vilaplana E, Alcolea D, Carmona-Iragui M, Sánchez-Saudinos MB, Sala I, Antón-Aguirre S, González S, Medrano S, Pegueroles J, Morenas E, Clarimón J, Blesa R, Lleó A, Alzheimer's Disease Neuroimaging Initiative.
    Ann Neurol; 2014 Aug 01; 76(2):223-30. PubMed ID: 24852682
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT, Koivisto AM, Hartikainen P, Helisalmi S, Soininen H, Herukka SK.
    J Alzheimers Dis; 2011 Aug 01; 25(4):583-94. PubMed ID: 21460434
    [Abstract] [Full Text] [Related]

  • 17. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J, Hluštík P, Zapletalová J, Strnad M, Stejskal D, Kaňovský P.
    J Neurol Sci; 2014 Aug 15; 343(1-2):120-4. PubMed ID: 24928081
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R, D'Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris JC, Holtzman DM.
    JAMA Neurol; 2016 May 01; 73(5):561-71. PubMed ID: 27018940
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.
    Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.
    Arch Neurol; 2001 Mar 01; 58(3):373-9. PubMed ID: 11255440
    [Abstract] [Full Text] [Related]

  • 20. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.
    J Alzheimers Dis; 2013 Mar 01; 33(1):117-31. PubMed ID: 22936010
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.